NSI 566

Drug Profile

NSI 566

Alternative Names: Adult neural stem cells - Neuralstem; hCNS-SC - Neuralstem; HuCNS-SC - Neuralstem; NSI-566/ALS; NSI-566/cSCI; NSI-566RSC

Latest Information Update: 24 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neuralstem
  • Developer CJ HealthCare; Emory University; Neuralstem; Neuralstem China; University of California, San Diego; University of Freiburg
  • Class Antidementias; Eye disorder therapies; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Neurogenesis stimulants; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Phase I/II Stroke
  • Phase I Spinal cord injuries
  • Preclinical Alzheimer's disease; Brain injuries; Cerebral palsy; Cognition disorders; Diabetic neuropathies; Huntington's disease; Lysosomal storage diseases; Multiple sclerosis; Optic neuritis; Paraplegia; Parkinson's disease

Most Recent Events

  • 22 Feb 2017 Neuralstem has patent protection for NSI 566 in USA
  • 23 Sep 2016 Phase-I/II development for Ischaemic stroke is ongoing in China (Neuralstem pipeline, September 2016)
  • 27 Jan 2016 Efficacy and pharmacodynamic data from a phase II trial in Amyotrophic lateral sclerosis released by Neuralstem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top